References
- International Agency for Research on Cancer. 2017. [cited 2017 Dec 12]. Available from: http://www.iarc.fr/
- Masters GA, Krilov L, Bailey HH, et al. Clinical cancer advances 2015: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015;33:786–809.
- Soverini S, De Benedittis C, Mancini M, et al. Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S120–8.
- Wang J, Wang B, Chu H, et al. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther. 2016;9:3711–3726.
- Martin LA, Ribas R, Simigdala N, et al. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun. 2017 Nov 30;8:1865.
- Kroemer G, Zitvogel L, Galluzzi L. Victories and deceptions in tumor immunology: stimuvax. Oncoimmunology. 2013;2:e23687.
- Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:822–835.
- Old LJ. Cancer immunology: the search for specificity–G. Cancer Res. 1981;41:361–375.
- Schvartsman G, Ferrarotto R, Massarelli E. Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Ther Adv Med Oncol. 2016;8:460–473.
- Park J, Kwon M, Shin EC. Immune checkpoint inhibitors for cancer treatment. Arch Pharm Res. 2016;39:1577–1587.
- Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18:1104–1115.
- Cella D, Grunwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:994–1003.
- Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
- Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol. 2017;10:174.
- Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577–581.
- Honeychurch J, Cheadle EJ, Dovedi SJ, et al. Immuno-regulatory antibodies for the treatment of cancer. Expert Opin Biol Ther. 2015;15:787–801.
- Muller M, Schouten RD, De Gooijer CJ, et al. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther. 2017;17:399–409.
- Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497–1508.
- Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33:23–35.
- Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19:5300–5309.
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–1356.
- Motzer RJ, Tannir NM, McDermott DF, et al . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-1290.
- Scherpereel A, Mazieres J, Laurent G, et al. Second- or third-line nivolumab vs. nivo plus ipilimumab in malignant pleural mesothelioma patients. J Clin Oncol. 2017;35(18_suppl):LBA8507–LBA8507.
- Dranitsaris G, Papadopoulos G. Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice? Appl Health Econ Health Policy. 2015;13:291–302.
- Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programs. Oxford,England: Oxford Univ. Press; 2005.
- Huang M, Lou Y, Pellissier J, et al. Cost effectiveness of pembrolizumab vs. Pharmacoeconomics. 2017;35:831–844.
- Sarfaty M, Leshno M, Gordon N, et al. Cost effectiveness of nivolumab in advanced renal cell carcinoma. Eur Urol. 2018;73:628–634.
- Miguel LS, Lopes FV, Pinheiro B, et al. Cost effectiveness of pembrolizumab for advanced melanoma treatment in Portugal. Value Health. 2017;20:1065–1073.
- Surveillance Epidemiology and End Results (SEER). National Cancer Institute. Washington, USA, 2012. [cited 2017 Dec 2]. Available From: http://seer.cancer.gov/
- Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98.
- Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551.
- NCCN clinical practice guidelines: Non small cell lung cancer. [cited2017 Dec 12]. Available from (https://www.tri-kobe.org/nccn/guideline/lung/english/non_small.pdf)
- Roche, Media Release, [updated 2017 Dec 11; cited 2017 Dec 7]. Available from: https://www.roche.com/media/store/releases/med-cor-2017-12-07.htm
- Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
- Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunotherapy. Science.. 2013;342:1432–1433.
- Kolassa EM. The strategic pricing of pharmaceuticals. Oxford MS: The Pondhouse Press; 2009.
- A Nation Challenged: the Treatment. Canada overrides patent for cipro to treat anthrax. New York Times, [updated2001 Oct 19cited Dec 7, 2017]; Available from: (http://www.nytimes.com/2001/10/19/business/nation-challenged-treatment-canada-overrides-patent-for-cipro-treat-anthrax.html)
- Shashikant S More countries use compulsory license, but new problems emerge. TWN info service on health issues no. 4. [updated 2005 May 19; cited 2017 Dec 7]. Available from: http://www.twnside.org.sg/title2/health.info/twninfohealth004.htm
- Bayer cancer drug faces new patent problems in India. The Pharma Letter, [updated 2017 April 10; Accessed 2017 Dec 7]. Available from: https://www.thepharmaletter.com/article/bayer-cancer-drug-faces-new-nexavar-patent-problems-in-india
- Indian court rejects Novartis patent. Nature News. [updated2013 April 1; cited 2017 Dec 7]. Available from: https://www.nature.com/news/indian-court-rejects-novartis-patent-1.12717
- Panditrao AM. Xtandi versus Indian patent laws: a persepective. Int J Appl Basic Med Res. 2017;7:1–2.
- Stat News. At $475,000, new cancer drug raises thorny questions about drug pricing — and value. [updated2017 Sep 4; cited 2017 Dec 7]. Available from: https://www.statnews.com/2017/09/04/cancer-drug-pricing-novartis/
- Dranitsaris G, Dorward K, Owens RC, et al. What is a new drug worth? An innovative model for performance-based pricing. Eur J Cancer Care. 2015;24:313–320.
- Clement FM, Harris A, Li JJ, et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. Jama. 2009;302:1437–1443.
- Stiglitz J Prizes not Patents. UpdatedMay 6, 2007; cited 2017 Dec 20. Available from: https://www.project-syndicate.org/commentary/prizes–not-patents?barrier=accessreg
- Srikanthan A, Mai H, Penner N, et al. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding. Curr Oncol. 2017;24:295–301.
- Yang YT, Chen B, Bennett CL. Biosimilars-curb your enthusiasm. JAMA Oncol. 2017;3:1467–1468.